Organon & Co. (OGN) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with OGN
Recent news

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
OGN

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
OGN

Is Trending Stock Organon & Co. (OGN) a Buy Now?
Is Trending Stock Organon & Co. (OGN) a Buy Now?
OGN

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
OGN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 56.85
- MACD 12/26/9
- 0.02
- EMA 9 of MACD
- 0.01
- MACD histogram
- 0.00
- SMA 50
- $13.69
- Price above SMA 50
- EMA 50
- $13.62
- Price above EMA 50
- SMA 200
- $11.03
- Price above SMA 200
- EMA 200
- $11.17
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.98 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
OGN

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
OGN

Is Trending Stock Organon & Co. (OGN) a Buy Now?
Is Trending Stock Organon & Co. (OGN) a Buy Now?
OGN

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
OGN

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
OGN

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
OGN

Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics
OGN

Organon (OGN) Lags Q2 Earnings Estimates
Organon (OGN) Lags Q2 Earnings Estimates
OGN

Organon Announces Quarterly Dividend
Organon Announces Quarterly Dividend
OGN

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
OGN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Organon & Co.
Organon & Co. is a global pharmaceutical company focused on advancing women's health and well-being. Spun off from Merck & Co., Inc. in 2021, Organon is dedicated to addressing unmet medical needs in areas such as contraception, fertility, menopause, and gynecological disorders. With a portfolio of products and research initiatives aimed at improving the lives of women at various stages of their lives, Organon is committed to advancing healthcare solutions that empower women and promote their overall health. The company's mission is to make a meaningful difference in women's lives through innovative medical advancements and a dedication to women's healthcare excellence worldwide.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Carrie Smith Cox | Executive Chair of the Board | 1959 |
| Mr. Joseph T. Morrissey Jr. | Chief Executive Officer | 1965 |
| Mr. Matthew M. Walsh C.F.A. | Executive VP & CFO | 1967 |
| Ms. Rachel A. Stahler | Executive VP, Chief Information Officer and Chief Digital & Growth Officer | 1976 |
| Mr. Kirke Weaver | Executive VP, General Counsel & Corporate Secretary | 1973 |
| Dr. Juan Camilo Arjona Ferreira M.D. | Executive VP, Head of Research & Development and Chief Medical Officer | 1971 |
| Ms. Jennifer Halchak | Head of Investor Relations | — |
| Mr. Daniel Karp | Chief Strategy Officer & Head of Corporate Development | 1978 |
| Mr. Aaron Falcione | Executive VP & Chief Human Resources Officer | 1971 |
| Mr. Vittorio Nisita | Executive VP and Head of Enterprise Services & Solutions | 1968 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 56.85
- MACD 12/26/9
- 0.02
- EMA 9 of MACD
- 0.01
- MACD histogram
- 0.00
- SMA 50
- $13.69
- Price above SMA 50
- EMA 50
- $13.62
- Price above EMA 50
- SMA 200
- $11.03
- Price above SMA 200
- EMA 200
- $11.17
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +10.7 | -21.3 | +6.0 | |||||||||
| 2022 | +2.4 | +13.2 | -6.8 | -8.0 | +18.3 | -10.6 | -7.4 | -10.4 | -18.8 | +8.8 | -1.4 | +5.7 |
| 2023 | +7.3 | -19.2 | -3.2 | +4.7 | -20.9 | +7.0 | +6.9 | +1.1 | -21.6 | -11.4 | -22.7 | +25.4 |
| 2024 | +13.2 | +1.0 | +7.1 | +0.6 | +13.3 | -3.2 | +7.6 | +3.2 | -13.4 | -0.3 | -12.2 | -4.2 |
| 2025 | +4.0 | +0.0 | +3.8 | -8.5 | -2.4 | +4.6 | -3.5 | -3.4 | +13.4 | -38.6 | +14.9 | -5.7 |
| 2026 | +18.0 | -11.1 | -16.7 | +115.8 | +0.4 | +1.3 | +0.1 | +1.5 | -0.4 | +0.3 |
Corporate actions
Upcoming
No upcoming corporate actions for OGN



